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Human serum albumin (HSA) has two primary binding sites for drug molecules. These sites selectively
bind different dansylated amino acid compounds, which—due to their intrinsic ﬂuorescence—have long
been used as speciﬁc markers for the drug pockets on HSA. We present here the co-crystal structures
of HSA in complex with six dansylated amino acids that are speciﬁc for either drug site 1 (dansyl-L-aspar-
agine, dansyl-L-arginine, dansyl-L-glutamate) or drug site 2 (dansyl-L-norvaline, dansyl-L-phenylalanine,
dansyl-L-sarcosine). Our results explain the structural basis of the site-speciﬁcity of different dansylated
amino acids. They also show that fatty acid binding has only a modest effect on binding of dansylated
amino acids to drug site 1 and identify the location of secondary binding sites.
 2010 Elsevier Inc. Open access under CC BY license.1. Introduction
With a typical circulating concentration of around 0.6 mM, HSA
is the most abundant protein in blood plasma and serves as an
important transporter molecule (Carter and Ho, 1994; Peters,
1995). The monomeric 67 kDa protein has three structurally
homologous a-helical domains (I-III), each subdivided into sub-do-
mains A and B (He and Carter, 1992) (Fig. 1). Despite these internal
architectural similarities, HSA has several distinct binding com-
partments distributed asymmetrically across the protein and can
accommodate a structurally diverse set of ligands. These ligands
nevertheless share the general property of being poorly soluble
hydrophobic compounds with anionic or electronegative features
and include non-esteriﬁed fatty acids, thyroxine, uremic toxins,
hemin and bilirubin (Peters, 1995). HSA greatly increases the solu-
bilising capacity of plasma for its cargo compounds, allowing them
to be present at near millimolar concentrations that are signiﬁ-
cantly in excess of their aqueous solubilities (Richieri and Kleinfeld,
1995; Spector, 1986). The binding capacity of HSA varies widely for
different ligands. For example, there are up to seven binding sites
for long-chain fatty acids, widely considered to be the primaryunology Laboratory (SPI-Lab),
sychiatry, King’s College London,
ur Lane, London SE5 9NU, United
iversity of Oxford, Mansﬁeld
 license.ligand of the protein (Bhattacharya et al., 2000b; Curry et al.,
1998); these sites, labelled FA1–FA7 (Fig. 1c), have variable binding
afﬁnities and are formed by residues from all six sub-domains
(Kragh-Hansen et al., 2006; Simard et al., 2006, 2005) (Fig. 1). In
contrast, there is only one primary site for large compounds such
as hemin (Wardell et al., 2002; Zunszain et al., 2003) or bilirubin
(Brodersen, 1980; Wells et al., 1982).
HSA can also bind drug compounds with similar physiochemi-
cal properties to its natural ligands and may signiﬁcantly impact
the kinetics of their distribution and elimination. Consequently,
the investigation of HSA–drug interactions has long been of major
interest to pharmaceutical scientists. One of the most important
breakthroughs in this area happened in the mid-1970s when Sud-
low and colleagues used a range of drugs and ﬂuorescent dansylat-
ed amino acids in competition binding experiments to identify two
primary drug-binding sites on HSA (Sudlow et al., 1975, 1976).
Later crystallographic analysis of complexes of HSA with speciﬁc
compounds conﬁrmed that drug sites 1 and 2, as they came to be
called, are located in sub-domains IIA and IIIA, respectively (He
and Carter, 1992) (Fig. 1b). More recently, extensive crystallo-
graphic studies of the binding of drugs and drug-like molecules
to HSA have conﬁrmed the primacy of drug sites 1 and 2 but also
identiﬁed additional binding sites across the protein (Bhattacharya
et al., 2000a; Hein et al., 2010; Lejon et al., 2008; Petitpas et al.,
2001, 2003; Zhu et al., 2008). Many of these additional sites are
likely to be secondary binding pockets, which are probably occu-
pied as a result of the high drug concentrations typically used to
prepare HSA–drug complexes for crystallographic work, though
sub-domain IB was recently identiﬁed as the primary binding site
for the steroid antibiotic, fusidic acid (Zunszain et al., 2008).
Fig.1. Location of binding sites for dansylated amino acids determined by X-ray crystallography. (a) Simulated annealing Fo  Fc omit map (contoured at 3r) showing DanF
bound to drug site 2 in sub-domain IIIA. DanF is shown in a stick representation with atoms coloured by atom-type: C – purple; O – red; and N – blue. Sub-domain IIIA is
shown in a ribbon representation (blue). Selected protein side-chains are shown as sticks, with carbon atoms coloured grey. (b) Overview of DanN bound to drug sites 1 and 2
in HSA. The ligands are shown in a stick representation with a semi-transparent molecular surface. The protein secondary structure is shown coloured by sub-domain. This
colour scheme is maintained throughout. (c) Overview of DanN bound to sub-domains IIA and IB in HSA–myristate. The seven fatty acid binding sites on the protein are
labelled FA1–FA7. (For interpretation of the references to colour in this ﬁgure legend, the reader is referred to the web version of this article.)
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structural impact of fatty acid binding on drug interactions with
the protein, an important consideration for physiological drug
binding which normally occurs in the presence of fatty acid.
Long-chain fatty acids bind with high afﬁnity to drug site 2 and will
therefore competitively displace such compounds (Simard et al.,
2006, 2005). In contrast, drug site 1 in sub-domain IIA has a low
afﬁnity for fatty acids and is unlikely to be occupied by this class
of ligand under normal physiological conditions. However, the
structure of the binding site is altered by binding of fatty acids to
a high-afﬁnity site nearby (FA2) Ghuman et al., 2005, an effect that
is likely to account for some observed differences in drug binding
in the presence of lipids (Birkett et al., 1977; Vorum and Honoré,
1996).
Although structural studies are a powerful way to locate ligand
binding sites on HSA, they remain technically challenging and are
hardly a convenient method for determining the binding location
of novel drug compounds (Curry, 2009). However, the dansylated
amino acids ﬁrst used by Sudlow and colleagues to determine
the number and speciﬁcity of the drug-binding sites on HSA re-
main useful tools for mapping drug-binding sites on the protein
since they can be targeted to speciﬁc binding pockets and, being
highly ﬂuorescent, can be used in high-throughput competition
binding assays (Sudlow et al., 1975, 1976). They have been in con-
tinuous use since their binding to HSA was ﬁrst characterised over
30 years ago (Chen and Guo, 2009; Lissi et al., 2009; Mathias and
Jung, 2007; Nakajou et al., 2003; Sakai et al., 2001; Thorarensen
et al., 2007; Yamasaki et al., 1996).
The physicochemical properties of the amino acid side chains of
the dansylated amino acids determine which drug-binding site
they bind. Those with hydrophobic side chains (e.g. dansyl-L-phen-
ylalanine (DanF) and dansyl-L-norvaline (DanNV)) are speciﬁc for
drug site 2, as do dansylated amino acids such as dansylsarcosine
(DanSRC) and dansyl-L-proline that have a methylated or blocked
a-amino group (Sudlow et al., 1975, 1976). In contrast, dansylated
amino acids with polar or charged side chains bind preferentially
to drug site 1 (e.g. dansyl-L-asparagine (DanN), dansyl-L-arginine
(DanR) and dansyl-L-glutamate (DanE)) (Sudlow et al., 1975, 1976).
Despite their evident utility in drug binding experiments, there
have been no investigations of the structural aspects of the interac-
tions of dansylated amino acids with HSA. Here we report the crys-
tal structures of HSA in complex with six different dansylated
amino acids that are speciﬁc either for drug site 1 (DanN, DanE,
DanR) or drug site 2 (DanF, DanNV and DanSRC). Our results
explain the structural basis of the site-speciﬁcity of these com-
pounds. They also reveal secondary binding sites for some com-pounds (DanN, DanF). In the case of DanN, we also show that,
although fatty acid binding induces restructuring of one ﬂanking
wall of drug site 1, it has minimal impact on the binding of the
dansylated compound to the pocket.
These structures represent the ﬁrst case of a group of structur-
ally related drug-like compounds being co-crystallised with HSA.
They provide new insights into the speciﬁcity determinants of
the drug-binding pockets and should help future investigations
of HSA–drug interactions.2. Materials and methods
Puriﬁed recombinant HSA was kindly provided by Prof. Eishun
Tsuchida (Waseda University) and, as Recombumin™, by Delta
Biotechnology Ltd. (Nottingham, England). HSA was ﬁrst defatted
(Sogami and Foster, 1968) and run on a Superdex S75 HR10/30
gel ﬁltration column to remove contaminating HSA dimers to en-
sure a purely monomeric preparation of the protein, as described
previously (Bhattacharya et al., 2000a; Curry, 2009). HSA used in
the crystallisation of HSA–myristate complexes did not require
defatting (Curry et al., 1998).
All dansylated amino acids were obtained from Sigma–Aldrich
at the highest available purity. For preparation of complexes with
defatted HSA the dansylated amino acids were typically dissolved
at 100 mM in dimethylsulphoxide (DMSO) (25 mM in the case of
DanN). Complexes with HSA were prepared by incubating the drug
at a 5:1 mol ratio with HSA, typically by mixing 500 lL 1.5 mM
HSA in 20 mM potassium phosphate, pH 7.0 with 37.6 lL
100 mM dansylated amino acid and incubating at room tempera-
ture for at least 1 h. The DMSO concentration was then reduced
to <0.1% (v/v) by repeated cycles of dilution in phosphate buffer
and re-concentration, as described previously (Ghuman et al.,
2005).
The crystallisation conditions used for both HSA–dansylated
amino acid and HSA–myristate complexes were the same as those
that have been published (Bhattacharya et al., 2000a,b; Ghuman
et al., 2005). To prepare ternary HSA–myristate–dansylated amino
acid complexes for DanN, DanE and DanR HSA–myristate crystals
were harvested into artiﬁcial mother liquor (typically 36% PEG
3350, 50 mM potassium phosphate pH 7.0) and then incubated
for 24–48 h in the same solution containing 5 mM of the dansylat-
ed amino acid, following a protocol developed earlier for HSA–
myristate–drug ternary complexes (Ghuman et al., 2005).
All crystals were mounted in thin walled glass capillaries
for data collection at room temperature. Data were collected at
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X11 at EMBL/DESY Hamburg (Germany). The data were processed
and scaled using the CCP4 software suite (Collaborative Computer
Project, 1994). In all cases the HSA–dansylated amino acid com-
plexes co-crystallised isomorphously in the P1 unit cell observed
previously for defatted HSA crystals (Bhattacharya et al., 2000a).
Diffraction data were phased by molecular replacement using the
structure of defatted HSA complexed with 3-carboxy-4-methyl-5-
propyl-2-furan-propanoic acid (PDB: 2BXA Ghuman et al., 2005),
stripped of its ligands. Crystals of HSA–myristate–dansylated ami-
no acid complexes had the C2 unit cell expected for HSA–myristate
crystals (Bhattacharya et al., 2000b). In this case the diffraction
data were phased using the structure of the HSA–myristate com-
plex (PDB: 1E7G Bhattacharya et al., 2000b), again minus its li-
gands. Model building was performed using O (Jones et al.,
1991). Coordinates for the dansylated compounds were generated
by modifying the structure of dansylglycine (Antolini et al., 1986),
which was obtained from the small molecule Cambridge structural
database via the Chemical Database Service (Fletcher et al., 1996).
All models were reﬁned using CNS (Crystallography and NMR
System) version 1.2 (Brünger et al., 1998).
3. Results
3.1. Structure determination
The dansylated amino acids DanN, DanSRC, DanNV and DanF
were co-crystallised with defatted HSA at a mole ratio of 5:1 (com-
pound:protein) and yielded crystals in space-group P1 with unit
cell dimensions that are essentially identical to crystals of HSA–
drug complexes obtained previously (Ghuman et al., 2005); these
have two HSA molecules in the asymmetric unit, giving two inde-
pendent structures of the HSA–dansylated amino acid complex.
HSA–myristate complexes were crystallised in space-group C2
(with one molecule per asymmetric unit) as described previously
(Bhattacharya et al., 2000b); DanN, DanE and DanR were added
by soaking these crystals in solutions containing 5 mM of the ﬂuo-
rescent compound (see Section 2). High concentrations of dansy-
lated amino acids were used in soaking and co-crystallisation
experiments to ensure full occupancy of the primary binding sites.Table 1
Data collection and reﬁnement statistics.
Dansyl-sarcosine Dansyl-Norvaline
Myristate  
Data collection
Space group P1 P1
Resolution range (Å) 52.0–2.9 49.6–2.45
Nrefs 27,597 42,048
Multiplicitya 1.9 (1.9) 1.8 (1.9)
Completeness (%)a 96.9 (98.4) 90.6 (85.6)
Rmerge (%)a, b 11.2 (37.1) 7.2 (51.0)
I/rI 6.6 (2.1) 9.7 (2.9)
Reﬁnement
No. atoms (exc. H) 8285 8481
No. of waters 26 28
Rmodel (%)c 22.0 22.8
Rfree (%)d 25.6 25.7
RMSbonds (Å) 0.009 0.009
RMSangles () 1.29 1.23
Average B-factor (Åb) 73.0 75.3
Ramachandran plote (%core/allowed) 87.3/12.2 88.6/10.8
PDB ID 2xvq 2xw1
a Values for the outermost resolution shell are given in parentheses.
b Rmerge (%) = 100 
P
h
P
j |Ihj  Ih|/
P
h
P
j Ihj, where Ih is the weighted mean intensit
c Rmodel (%) = 100 
P
hkl |Fobs  Fcalc|/
P
hkl Fobs, where Fobs and Fcalc are the observed a
d Rfree (%) is the Rmodel (%) calculated using a randomly selected 5% sample of reﬂectio
e Numbers determined using Procheck (Laskowski et al., 1993).In all seven cases Fourier difference electron density maps cal-
culated following phasing by molecular replacement (Section 2)
clearly indicated the location of at least one bound dansylated ami-
no acid molecule. In combination with inspection of the chemistry
of the binding environment, this provided an unambiguous deter-
mination of the drug binding conformation (Fig. 1a). For several of
the complexes, density indicating the occupancy of secondary
binding sites was also observed; where this occurred, an additional
molecule of the dansylated amino acid was built into the model
(Fig. 1b and c). Reﬁnement of the different complexes against data
with high-resolution limits in the range 2.4–2.9 Å produced mod-
els with good stereochemistry and Rfree values in the range of
24.8–25.6%. Full data collection and reﬁnement statistics are given
in Table 1.3.2. Drug site 1 speciﬁc dansylated amino acids
The structure of DanN bound to defatted HSA (Fig. 2a) shows
that the dansyl group binds in the centre of drug site 1 in sub-do-
main IIA between the side-chains of Ala-291 and Leu-238; the
plane of the dansyl ring is approximately perpendicular to the line
connecting the Ca atoms of this pair of residues. This group there-
fore binds in the same position and planar orientation as observed
for the major aromatic moieties of many other site 1 drugs, includ-
ing warfarin and azapropazone (see Section 4) (Fig. 1b) Ghuman
et al., 2005; Petitpas et al., 2001. The dimethylamine group of the
dansyl ring occupies what was previously termed the right hand
sub-chamber (Ghuman et al., 2005), close to the side-chains of
Leu-260, Ala-261, Ser-289 and the aliphatic portion of Arg-257.
The other end of the molecule is positioned close to the polar en-
trance to the binding pocket. The amide nitrogen of the sulphona-
mide moiety forms a hydrogen bond with the backbone carbonyl of
Ala-291, while one of the two SO2 oxygen atoms receives a hydro-
gen bond from the side-chain of Arg-222 on one side of the pocket
entrance. The carboxylate group of the amino acid makes two salt
bridges with basic side-chains, Lys-199 and Arg-222. In addition
the carbonyl group of the Asn side-chain of DanN is hydrogen
bonded to Lys-199. Unusually among drugs that have been ob-
served through crystallography to bind to site 1, DanN does notDansyl-Phe Dansyl-Asn Dansyl-Asn Dansyl-Arg Dansyl-Glu
  + + +
P1 P1 C2 C2 C2
44.5–2.4 35.1–2.6 22.5–2.4 32.6–2.65 21.4–2.7
49,448 37,571 25,305 19,137 18,820
1.8 (1.8) 2.0 (2.0) 1.9 (1.9) 2.7 (2.7) 2.8 (2.8)
88.0 (78.2) 97.7 (97.4) 96.3 (96.7) 97.4 (99.)) 98.5 (99.3)
8.4 (38.2) 4.6 (38.5) 4.0 (31.4) 6.3 (40.0) 5.9 (32.3)
8.3 (1.4) 10.4 (2.3) 11.4 (2.6) 10.6 (2.8) 12.1 (3.6)
8440 8327 4775 4607 4630
18 35 39 23 32
22.8 20.7 20.6 19.1 19.0
25.6 24.8 25.0 25.2 25.1
0.009 0.007 0.007 0.007 0.007
1.26 1.22 1.23 1.22 1.24
73.4 64.8 54.4 56.2 54.0
89.2/10.1 89.7/9.7 91.9/7.9 91.7/7.9 90.1/9.9
2xw0 2xvu 2xvv 2xvw 2xsi
y of the symmetry related reﬂections Ihj.
nd calculated structure factors, respectively.
n data omitted from reﬁnement.
Fig.2. Binding interactions made by dansylated amino acids (DanN, DanE, DanR) in drug site 1 (sub-domain IIA) of HSA in the absence and presence of fatty acid. (a) Binding
of DanN (coloured by atom type as in Fig. 1b). Hydrogen bonds are shown as dotted cyan lines. (b) Comparison of the binding of DanN and warfarin (Petitpas et al., 2001). The
view is rotated slightly to the left compared to panel a; the polypeptide containing Y150 has been removed for clarity. (c) Binding of DanN to HSA in the presence of myristate
(shown as CPK spheres, coloured by atom type: carbon – grey and oxygen – red). (d) Comparison of the binding of DanN, DanE and DanR to HSA–myristate. (For interpretation
of the references to colour in this ﬁgure legend, the reader is referred to the web version of this article.)
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defatted HSA (Ghuman et al., 2005).
Surprisingly, since DanN is classiﬁed as a compound that is spe-
ciﬁc for drug site 1, the electron density map for the HSA–DanN
complex clearly shows the presence of a second DanN molecule,
bound to drug site 2 in sub-domain IIIA. This is likely to be a lower
afﬁnity binding site for DanN since competition binding experi-
ments performed using a 1:10 molar ratio of DanN to HSA only de-
tected signiﬁcant displacement by drugs speciﬁc for drug site 1 in
sub-domain IIA (Sudlow et al., 1976). This secondary site for DanN
is probably only occupied because of the high concentrations of the
ligand used in the preparation of the complex (see Section 2). The
details of binding of DanN to drug site 2 will be described below in
conjunction with the comparison of the binding interactions made
by the three dansylated amino acids that are speciﬁc for that site
(DanF, DanNV, DanSRC).
In the structure of the ternary HSA–myristate–DanN complex
there are six molecules of fatty acid, bound to fatty acid sites 1–6
(FA1–6) Bhattacharya et al., 2000b; Curry et al., 1999 (Fig. 1c). A
molecule of DanN is observed bound to drug site 1 but the struc-
ture reveals that binding of fatty acid to sites FA3 and FA4 in
sub-domain IIIA, which overlap extensively with drug site 2, pre-vented DanN from binding to this region of the protein. In contrast,
although drug site 1 overlaps with site FA7, it has low afﬁnity for
fatty acid (Simard et al., 2006) and under our experimental condi-
tions the dansylated amino acid is able to displace the lipid. These
observations are consistent with drug site 1 being a high-afﬁnity
site for DanN (Fig. 1b and c).
Interestingly, a second molecule of DanN is observed bound in
the HSA–myristate–DanN complex in direct contact with the myr-
istate molecule in site FA1 (sub-domain IB) (Fig. 1c; Supp. Fig. 1).
Since DanN is not observed to bind to this site in the absence of
fatty acid, this binding appears to be the result of a cooperative
interaction between the dansylated compound and the fatty acid.
Although the binding of myristate to HSA causes signiﬁcant
conformational changes in the protein that have a large impact
on drug site 1 (Ghuman et al., 2005), the structure of the HSA–myr-
istate–DanN complex reveals that fatty acid binding results in only
very modest changes in the mode of binding of the dansylated ami-
no acid to this site (Fig. 2c). The conformational changes are lo-
cated on one ﬂank of the binding pocket within sub-domain IIA
and principally involve re-orientation or relocation of the side-
chains of Tyr-150, Glu-153, Gln-196 and Arg-257. These form a
fairly polar ﬂanking wall but, apart from Arg-257, do not contact
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the position of the bound DanN upon addition of myristate are
minimal. The compound is shifted slightly (0.4 Å) towards the po-
lar mouth of the pocket but maintains the hydrogen bonds that
were observed in the defatted HSA–DanN complex (although the
hydrogen bond between the side-chain of Arg-222 and the sulph-
onamide oxygen is stretched from 2.6 Å to 3.3 Å). There is a slight
adjustment of the position of the Asn side-chain in DanN but the
hydrogen bond with Lys-199 is preserved.
The structures of the HSA–myristate–DanE and HSA–myristate–
DanR ternary complexes reveal exactly the same pattern of ligand
binding as was observed for DanN: sites FA1–6 are occupied by
lipid and molecules of the dansylated amino acid are found in
sub-domain IIA (drug site 1) and in contact with myristate in
sub-domain IB. The dansyl groups of DanE and DanR bind in the
same positions as observed for DanN in both of these sites and
make the same speciﬁc hydrogen bonding interactions with the
protein. It seems clear that this moiety provides important anchor-
ing interactions with the protein.
As might be expected, the interactions made by the amino acid
side-chains of the dansylated compounds show more variability.
Although the Glu side-chain of DanE interacts with Lys-199 (as ob-
served for Asn side-chain of DanN), the Arg side-chain of DanR
adopts a more extended conformation, allowing the guanidinium
group to make a salt-bridge—albeit a long one (3.5 Å)—with the
side-chain of Glu-153 (Fig. 2d).
What would be the interactionsmade by DanE and DanR in drug
site 1 in the absence of fatty acid? Since themode of binding of DanN
was found to be essentially unaffected by fatty acid binding to HSA
and DanE makes essentially the same set of interactions with the
drug binding pocket, it seems likely that bound conformation of
DanEwouldbeunchanged indefattedHSA. It ismoredifﬁcult to pre-
dict the binding mode for DanR, since it is observed to interact with
the side-chain of Glu-153, a residue that is normally tied up in an
interaction with His-288 in defatted HSA (Ghuman et al., 2005).
However, modelling of the bound conformation of DanR into drug
site 1 in the defatted protein shows that there is ample room for
the Arg side-chain and the possibility of a speciﬁc hydrogen bond
interaction with the side-chain of Ser-192. It is therefore likely to
be able to bind to drug site 1 in the absence of fatty acid.
The ability of drug site 1 in HSA to bind dansylated amino acids
with a range of polar side-chains appears to be due to the large size
of the pocket, which can accommodate medium and large-sized
side-chains and to the fact that it possesses polar groups that pro-
vide counter-charges to stabilise the side-chains on the dansylated
compounds (Fig. 2d).
Comparison of the binding of DanN, DanE and DanR to sub-do-
main IB in the HSA complexes with myristate reveals that the dan-
syl moieties bind in exactly the same way—in contact with the
myristate molecule (site FA1)—but that the amino acid groups
are all exposed to solvent and their side-chains make no signiﬁcant
contact with the protein (Supp. Fig. 1). This secondary binding site
is also observed to be occupied in HSA–myristate by other com-
pounds that are speciﬁc for drug site 1 (e.g.warfarin, indomethacin
and salicylate) (Ghuman et al., 2005; Petitpas et al., 2001; Zhu
et al., 2008). It is probably not physiologically signiﬁcant for these
compounds or dansylated amino acids because their binding is
dependent on contacts with bound lipid which is unlikely to be
present under normal conditions due to the low afﬁnity of site
FA1 for fatty acids (Simard et al., 2006).
3.3. Drug site 2 speciﬁc dansylated amino acids
Since fatty acid binding sites FA3 and FA4 in sub-domain IIIA
overlap extensively with drug site 2, the binding of dansylated
compounds speciﬁc for drug site 2 was examined by co-crystallis-ing them with defatted HSA (Section 2). Three binary complexes
were investigated; two of these had large hydrophobic side-chains
on the amino acid group (DanF, DanNV), while the third (DanS-
RC)—a derivative of dansylglycine—has a methylated amide group.
As was observed for dansylated amino acids bound to drug site
1, the dansyl group provides the most important anchoring inter-
actions for binding DanF, DanNV and DanSRC in drug site 2
(Fig. 3). In each case the dansyl group occupies the same position
in the binding site pinned between the side-chains of Asn-391
and Phe-403 on one side and Leu-453 on the other. The dimethyl-
amine group occupies the deepest part of the pocket, contacting
the apolar side-chains of Ile-388, Val-433 and the disulphide bond
formed by Cys-393 and Cys-438. The dansyl group occupies the
same part of the pocket as the major aromatic moieties of
diazepam, diﬂunisal, ibuprofen, propofol and indoxyl sulphate
(Bhattacharya et al., 2000a; Ghuman et al., 2005). Because of the
presence of the dimethylamine group the fused ring system of
the dansyl group is displaced relative to the bound position of
the indole ring of indoxyl sulphate (Fig. 3b); nevertheless the SO2
group of the dansylated amino acids occupies the same position
as the SO3 group of indoxyl sulphate and interacts with some of
the same polar groups near the mouth of the pocket. For all three
dansylated amino acids the oxygen atom on one side of the SO2
group makes a hydrogen bond with the side-chain of Tyr-411.
The other oxygen atom of the SO2 makes a 3.0 Å hydrogen bond
to the hydroxyl group of Ser-489 in the case of DanF; however,
the distance between these groups is stretched to 3.7 Å for DanNV
and to 4.1 Å for DanSRC. The variability in the orientations of the
SO2 groups arises because of the differential positioning of the ami-
no acid groups of the different dansyl compounds (Fig. 3c); this
also has some impact on the position of their amino acid carboxyl-
ate groups, though they all maintain a single salt-bridge to the
side-chain of Lys-411.
In all three structures accommodation of the amino acid moiety
results in displacement of the side-chain of Arg-410 from the posi-
tion that it is observed to occupy in defatted HSA or in complexes
with smaller site 2 drugs such as diﬂunisal, ibuprofen or indoxyl
sulphate, which rely on the Arg side-chain for at least one hydro-
gen bond interaction (Bhattacharya et al., 2000a; Ghuman et al.,
2005). In the presence of DanF, DanNV or DanSRC, the side-chain
of Arg-410 is rotated towards the solvent or becomes disordered.
This rotation reveals a hydrophobic ﬂanking wall of drug site 2 that
has not previously been noted but which contacts the apolar side-
chains of DanF and DanNV and the methyl group added to the sul-
phonamide in DanSRC. The main contacts made by these apolar
functional groups are with the hydrophobic side chains of
Leu-396, Phe-403, Ala-406, Leu-407 and the apolar stem of Arg-
410 (Fig. 3b,c). However, this hydrophobic ﬂank of drug site 2 is
not sufﬁcient for complete burial of the side-chains of the dansy-
lated amino acids, which remain partly exposed to solvent. This
partial solvent exposure of the side chains binding within this
pocket may explain why the afﬁnity of DanF for this site is similar
to that of DanSRC even though DanSRC has no side chain (Sudlow
et al., 1975).
Asmentionedabove, drug site 2 is a secondary site for thebinding
of the site 1 speciﬁc compounds, DanN. The dansylated moiety of
DanN binds to the pocket in exactly the same way as observed for
DanF, DanNV and DanSRC (Fig. 3d). However, the polar Asn side-
chain of DanN is rotated relative to the conformations observed for
the side-chains of DanF and DanNV and does not make contact with
the hydrophobic ﬂank formed by Leu-396, Phe-403, Ala-406,
Leu-407. Although the Asn side-chain can make a single, elongated
hydrogen bond (3.2 Å) with the side-chain of Asn-391 (Fig. 3d) this
is appears insufﬁcient to overcome its inability to make favourable
apolar contactswith the pocket and probably accounts for the lower
afﬁnity of DanN for drug site 2 (Sudlow et al., 1975).
Fig.3. Binding interactions made by dansylated amino acids (DanSRC, DanNV, DanF and DanN) in drug site 2 (sub-domain IIIA) of HSA. (a) Binding of DanF (coloured by atom
type as in Fig. 1a). Hydrogen bonds are shown as dotted cyan lines. (b) Comparison of the binding of DanF and indoxyl sulphate (IDS) Ghuman et al., 2005; carbon atoms in IDS
are coloured dark yellow. (c) Comparison of the binding of DanF, DanNV and DanSRC to drug site 2 of HSA. (d) Comparison of the binding of DanF and DanN to drug site 2 o
HSA. (For interpretation of the references to colour in this ﬁgure legend, the reader is referred to the web version of this article.)
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the HSA–DanF complex, bound to drug site 1 (Supp. Fig. 2). In this
case, however, it adopted a binding conformation that was very
different from that observed for dansylated compounds that are
speciﬁc for drug site 1. Instead of pinning the dansyl moiety in po-
sition — in the manner observed for DanN, DanE and DanR — the
side-chains of Leu-238 and Ala-291 are found to hold the Phe
side-chain of DanF. The dansyl group of DanF is re-located to the
lower part of drug site 1, which was previously observed to be
occupied by indomethacin (Ghuman et al., 2005); as with indo-
methacin, the binding of DanF induces a rotation of the side-chain
of Trp-214 (140 about x2). Since DanF was found not to be dis-
placed by binding of drugs speciﬁc to site 1 (Sudlow et al., 1976),
we conclude that the afﬁnity of this compound for site 1 is much
less than its afﬁnity for drug site 2.
It should be noted that the electron density maps also suggest
that a molecule of DanNV may also bind weakly to drug site 1.
However, although there is broken density to indicate low occu-
pancy binding of DanNV to the pocket, it was too weak to allow
reliable model building and the molecule was omitted from the
reﬁned structure.f4. Discussion and conclusions
Thirty-ﬁve years after the establishment of dansylated amino
acids as useful ﬂuorescent markers for the two primary drug-bind-
ing sites on HSA (Sudlow et al., 1975), we have used X-ray crystal-
lography to examine the structural basis for their site selectivity.
The results presented here provide a clear explanation for the spec-
iﬁcity of the dansylated amino acids characterised in the original
work of Sudlow and colleagues (Birkett et al., 1977; Sudlow
et al., 1975, 1976).
Dansylated amino acids speciﬁc for drug site 1 in HSA generally
have polar side-chains which can be uncharged or positively or
negatively charged, although dansyl-L-a-alanine or dansylgly-
cine—which have small apolar side-chains—are also speciﬁc for
this site (Fig. 2). Our results reveal that such compounds bind pref-
erentially to drug site 1 since this pocket can accommodate the
dansyl moiety in its central hydrophobic compartment in an orien-
tation that allows the pocket to make speciﬁc hydrogen-bond
interactions to the SO2 and amide groups of the sulphonamide
90 A.J. Ryan et al. / Journal of Structural Biology 174 (2011) 84–91moiety and to the common carboxylate group of the amino acid.
Moreover, these anchoring interactions allow the polar amino
acids groups of the ligand to be positioned within a hydrophilic
sub-chamber that is both large enough to accommodate the vari-
ably-sized side-chains and contains counter-charges that favour
their binding. Although the polar ﬂanking wall of drug site 1 which
interacts with the amino-acid side chains alters in composition
upon fatty acid binding, this was found to have a minimal effect
on the interactions made by the Asn side-chain of DanN; no steric
clashes are introduced and the physicochemistry of the wall re-
mains predominantly polar.
The bound orientation that is common to DanN, DanE and DanR
is unlikely to be adopted by dansylated amino acids that have large
apolar side-chains since this would place the side-chain in an unfa-
vourable binding environment. Accordingly, we did not observe
electron density to indicate binding of DanF or DanNV in this ori-
entation in drug site 1.
The presence of a conserved hydrogen bond formed from the
central amide group of the dansylated amino acids to the main-
chain carbonyl oxygen of Ala-291 in site 1 explains why DanSRC
does not bind to this pocket on HSA (Fig. 2a). Since the amide group
in DanSRC is blocked by a methyl group, it cannot make this hydro-
gen bond interaction; indeed, our structural results show that
methylation of the amide would create a steric clash with Ala-
291 preventing the dansyl group of DanSRC from adopting the con-
formation favoured by site 1 speciﬁc compounds such as DanN,
DanE and DanR (Sudlow et al., 1975, 1976). Similarly, blocking of
the amide by a hydrophobic group in dansyl-L-proline, which is
structurally similar in this respect to DanSRC, probably accounts
for its inability to bind to site 1 and its preference for site 2 (Sud-
low et al., 1975, 1976).
The central chamber in drug site 1 that is occupied by the dan-
syl groups of DanN, DanE and DanR overlaps extensively with the
binding loci of many different drugs that are speciﬁc for that site,
including azapropazone, phenylbutazone, oxyphebutazone, warfa-
rin and iodipamide (Ghuman et al., 2005; Petitpas et al., 2001)
(Fig. 2b). This readily explains the displacement of the ﬂuorescent
dansylated amino acids in drug competition binding assays (Sud-
low et al., 1975, 1976). However, our results are not consistent
with an earlier report, based on competition binding experiments,
which concluded that the portion of drug site 1 bound by DanN did
not overlap with the binding sites for warfarin or iodipamide
(Yamasaki et al., 1996). The reason for the discrepancy between
the structural and binding data is not entirely clear at present;
one possibility is that the interpretation of the binding data may
have taken full account of the presence of secondary binding sites
for these compounds.
Even drugs that do not bind primarily to the central chamber
may be expected to displace dansylated compounds from drug site
1. Indomethacin binds in the lower compartment of site 1 which is
generally not occupied by polar dansylated amino acids (Ghuman
et al., 2005); nevertheless superposition of the structures suggests
that the carboxylate group of the drug would make a steric clash
with the carboxylate moiety of the dansylated compounds. This
drug would therefore be predicted to displace the reporter
compounds.
Fatty acid binding is reported to cause up to a ﬁvefold enhance-
ment of the ﬂuorescence of dansylated compounds that bind to
drug site 1 (Birkett et al., 1977; Sudlow et al., 1976). Since the
bound orientation of DanN was not observed to be greatly altered
in the presence of fatty acids, this ﬂuorescence enhancement ap-
pears to arise because of changes in the immediate environment
of the dansyl group, due to the restructuring of polar ﬂank of the
binding site. A major factor may be the re-positioning of the guani-
dium group of Arg-257, which moves from 8 Å to 4 Å away from
the dansyl group of DanN upon fatty acid binding (Fig. 2a and c).In drug site 2 the dansylated moiety is again observed to be
responsible for establishing a common mode of binding by secur-
ing the compound within the main hydrophobic compartment of
the drug pocket (Fig. 3). In this case the hydrophobic side-chains
of the amino acids are thereby placed in contact with an apolar
ﬂanking wall that is revealed by the displacement of Arg-410 upon
binding of DanF, DanNV or DanSRC.
As found for drug site 1 the location of the dansyl group of the
dansylated amino acid bound to drug site 2 overlaps extensively
with the positions occupied by site 2 drugs or toxins such as ibu-
profen, diﬂunisal, diazepam, indoxyl sulphate or propofol, readily
accounting for the utility of DanF, DanNV and DanSRC as speciﬁc
markers for drug site 2 (Sudlow et al., 1975, 1976) (Fig. 3b). It is
interesting to note that other apolar dansylated amino acids, par-
ticularly dansyl-L-valine and dansyl-L-leucine that have branched
side-chains, bind more weakly to drug site 2 and exhibit some
binding to drug site 1 (Sudlow et al., 1976). At present it remains
a puzzle why these compounds are signiﬁcantly less speciﬁc for
drug site 2.
Although the polar DanN was also observed to bind to drug site
2 under our experimental conditions, it cannot exploit the apolar
feature of the pocket (Fig. 3d). This suggests it binds weakly, con-
sistent with the observation that binding of the ﬂuorescent com-
pound was unaffected by site 2 speciﬁc drugs such as ﬂubiprofen
or ibuprofen under experimental conditions that were sufﬁcient
to detect displacement by site 1 speciﬁc compounds (e.g. warfarin)
Sudlow et al., 1976. It is reasonable to assume that DanN can con-
tinue to be used as a speciﬁc marker for drug site 1.
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